Last updated: September 7, 2026
Meropenem/vaborbactam, marketed in the United States as Vabomere, is a hospital-focused carbapenem and beta-lactamase inhibitor combination used primarily against serious infections caused by carbapenem-resistant Enterobacterales, especially KPC-producing organisms. Its commercial profile is defined by high clinical value in a narrow resistant-pathogen segment, intense competition from other novel beta-lactam combinations, restricted hospital formularies, and limited public visibility into product-level revenue.
The product received FDA approval in August 2017 and obtained Qualified Infectious Disease Product exclusivity. Regulatory exclusivity expired in 2022, but Orange Book-listed patent protection extends into the early 2030s. The principal commercial risk is not immediate patent expiry. It is the combination of hospital budget pressure, antimicrobial-stewardship restrictions, competitive products, and the emergence of alternative agents.
What is meropenem/vaborbactam and how does it work?
Meropenem/vaborbactam combines the carbapenem antibiotic meropenem with vaborbactam, a cyclic boronic acid beta-lactamase inhibitor.
| Attribute |
Meropenem/vaborbactam |
| Brand |
Vabomere |
| Active ingredients |
Meropenem and vaborbactam |
| Developer history |
Rempex Pharmaceuticals, The Medicines Company, Melinta Therapeutics |
| FDA approval |
August 29, 2017 |
| Initial indication |
Complicated urinary tract infections, including pyelonephritis |
| Current clinical use |
Serious infections caused by susceptible resistant Gram-negative bacteria |
| Typical adult dose |
4 grams intravenously every eight hours, infused over three hours |
| Primary resistance target |
KPC-producing carbapenem-resistant Enterobacterales |
| Administration |
Hospital-based intravenous therapy |
| Biosimilar relevance |
None; this is a small-molecule antibacterial, not a biologic |
Vaborbactam inhibits class A serine beta-lactamases, including Klebsiella pneumoniae carbapenemases, or KPC enzymes. It does not restore meropenem activity against every mechanism of carbapenem resistance. Activity can be limited by metallo-beta-lactamases, OXA-type enzymes, porin loss, efflux mechanisms, and non-beta-lactam resistance pathways.
The product’s commercial value therefore depends on microbiology and local resistance patterns rather than broad empiric use.
What is the FDA regulatory status of Vabomere?
The FDA approved Vabomere through the conventional new drug application pathway in 2017. The approval was supported by clinical data in complicated urinary tract infection and by the product’s activity against resistant Enterobacterales.
Vabomere also qualified as a Qualified Infectious Disease Product under the Generating Antibiotic Incentives Now Act. That designation provided an additional five years of exclusivity and priority review benefits. The five-year QIDP period ran from the 2017 approval and expired in 2022.[1]
The product is not a biologic and does not qualify for the abbreviated biosimilar pathway. Potential competitors must generally pursue an abbreviated new drug application or another small-molecule regulatory route.
What indications and label limitations affect demand?
Vabomere’s commercial demand is concentrated in:
- Complicated urinary tract infections caused by resistant Enterobacterales.
- Hospital-acquired and ventilator-associated infections treated under institutional protocols.
- Bloodstream and intra-abdominal infections where susceptibility testing supports use.
- KPC-producing CRE infections for which clinicians prefer a targeted beta-lactam/beta-lactamase inhibitor.
The drug is administered intravenously and generally requires a three-hour infusion. That limits outpatient use and increases pharmacy and nursing resource requirements. Renal-dose adjustment is required, which is important because many target patients have acute kidney injury or chronic renal impairment.
What patents protect meropenem/vaborbactam?
The core U.S. patent estate includes patent protection covering vaborbactam and pharmaceutical compositions containing the combination. The key Orange Book-listed patent commonly associated with Vabomere is U.S. Patent No. 9,309,314, with an expiration date in 2032, subject to applicable patent-term adjustment and regulatory calculations.[2]
| Patent or protection |
Subject matter |
Approximate U.S. status |
| U.S. Patent No. 9,309,314 |
Vaborbactam and related pharmaceutical compositions |
Expiration in 2032, subject to term calculation |
| QIDP exclusivity |
FDA regulatory exclusivity for qualified antibacterial product |
Expired in 2022 |
| Clinical investigation exclusivity |
Approval-related exclusivity associated with the original indication |
Expired or no longer a principal barrier to ANDA entry |
| Orange Book listing |
Patent notice for the approved product |
Supports a patent-certification requirement for ANDA applicants |
The distinction between regulatory exclusivity and patent protection is commercially important. Generic applicants could begin challenging the product after regulatory exclusivity ended, but a successful launch before 2032 would require overcoming the listed patent or obtaining a license or settlement.
A later patent expiry does not guarantee uninterrupted commercial protection. Patent validity, claim scope, terminal disclaimers, patent-term adjustment, pediatric extensions, and any litigation settlement terms determine the actual launch date.
When does meropenem/vaborbactam lose exclusivity?
Vabomere lost its principal FDA regulatory exclusivity in 2022. The primary listed patent protection extends to approximately 2032.
| Milestone |
Date or period |
| FDA approval |
August 29, 2017 |
| QIDP five-year exclusivity |
Through approximately August 2022 |
| Potential ANDA filing window |
Open after applicable regulatory exclusivity restrictions |
| Core patent expiry |
Approximately 2032 |
| Earliest practical generic competition |
Dependent on Paragraph IV challenges, litigation, settlement, and final patent validity |
The most likely generic-entry scenarios are:
- A Paragraph IV applicant challenges the core patent and wins or obtains a favorable settlement.
- The applicant certifies that the patent is not infringed, invalid, or unenforceable, and the sponsor does not obtain an injunction.
- A generic launches after the patent expires.
- The patent holder grants a license with an agreed launch date before expiry.
The product does not face the same immediate patent cliff as a conventional small molecule whose last patent expires shortly after regulatory exclusivity. The commercial exposure is more likely to build through Paragraph IV activity before 2032.
Are there Paragraph IV challenges or patent litigation affecting Vabomere?
A publicly visible, market-defining Vabomere patent litigation event has not produced the same level of disclosure as the major litigation surrounding large pharmaceutical products. The Orange Book listing nevertheless creates a clear legal pathway for ANDA challenges.
A Paragraph IV certification would require the applicant to notify the patent holder and NDA holder. The patent holder could then file an infringement action, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman Act.[3]
The legal value of the patent estate depends on whether the claims cover:
- Vaborbactam itself.
- Stable pharmaceutical formulations.
- The meropenem/vaborbactam combination.
- Specific ratios or dosage forms.
- Manufacturing processes.
- Treatment of beta-lactamase-producing infections.
If the estate is concentrated in composition-of-matter claims, invalidity risk may be lower than for later formulation or method-of-use claims. If the core claims are narrow or vulnerable to obviousness arguments, an ANDA challenge could accelerate generic competition.
How strong is the meropenem/vaborbactam patent estate?
The estate has meaningful duration but a narrower commercial base than the estates of high-volume outpatient drugs.
Strengths
- The core patent extends well beyond the 2022 regulatory-exclusivity expiry.
- The product has a differentiated target against KPC-producing organisms.
- Intravenous combination products are technically more complex than standard oral generics.
- Manufacturing, sterile filling, analytical testing, and stability requirements can increase generic development costs.
Weaknesses
- Vaborbactam is a small molecule with a conventional ANDA pathway.
- Regulatory exclusivity has expired.
- Hospital purchasers can switch among several competing intravenous agents.
- Formulation and manufacturing complexity may create commercial barriers but does not prevent an approved generic.
- Clinical differentiation is strongest in a defined resistance mechanism rather than across all resistant Gram-negative infections.
The patent estate is best characterized as commercially relevant but not impregnable. Its economic value depends on the timing of ANDA filings and the ability of the owner to defend the core claims.
What formulations are protected by Vabomere patents?
Vabomere is supplied as an intravenous powder for reconstitution and dilution. The commercial formulation must maintain the stability and compatibility of meropenem and vaborbactam during preparation, infusion, and storage.
Potential formulation barriers include:
- Co-formulation stability.
- Sterile powder manufacture.
- Reconstitution performance.
- Container-closure integrity.
- Infusion-bag compatibility.
- Impurity control.
- Shelf-life validation.
These requirements can delay a generic competitor, but they do not create biologic-style interchangeability barriers. A generic manufacturer that demonstrates pharmaceutical equivalence, bioequivalence where applicable, and manufacturing compliance can compete through the ANDA pathway.
No biosimilar market exists for Vabomere. The relevant competitive risk is generic substitution and therapeutic substitution among branded reserve antibiotics.
How does Vabomere compare with competing antibiotics?
Vabomere competes in the hospital market for resistant Gram-negative infections. The leading alternatives include Avycaz, Recarbrio, Fetroja, and Zerbaxa.
| Product |
Active ingredients |
Primary resistance positioning |
Commercial implication |
| Vabomere |
Meropenem/vaborbactam |
Strong KPC activity |
Benefits from KPC-focused use and meropenem familiarity |
| Avycaz |
Ceftazidime/avibactam |
KPC, some OXA-48 activity |
Broad competitive overlap; established hospital presence |
| Recarbrio |
Imipenem/cilastatin/relebactam |
Certain carbapenem-resistant pathogens |
Competes where imipenem-based therapy is preferred |
| Fetroja |
Cefiderocol |
Difficult-to-treat resistant Gram-negative organisms, including some metallo-beta-lactamases |
Differentiated against resistance mechanisms not covered by Vabomere |
| Zerbaxa |
Ceftolozane/tazobactam |
Difficult-to-treat Pseudomonas and selected Enterobacterales |
Stronger positioning in some Pseudomonas cases |
Vabomere’s central advantage is activity against KPC-producing CRE combined with the familiarity of meropenem. Its main limitation is incomplete coverage of other resistance mechanisms, particularly metallo-beta-lactamases.
Clinical guidelines generally favor use of active novel beta-lactam agents over older, more toxic regimens when susceptibility is confirmed. The Infectious Diseases Society of America has identified meropenem/vaborbactam as a preferred treatment option for infections caused by KPC-producing CRE in appropriate clinical settings.[4]
Which companies are challenging or competing with Vabomere?
The competitive field includes:
- Pfizer, through Avycaz.
- MSD, through Recarbrio.
- Shionogi, through Fetroja.
- Merck and other commercial partners involved in Gram-negative antibacterial development.
- Generic manufacturers that may pursue meropenem/vaborbactam ANDAs after regulatory exclusivity.
The market is not controlled by a single product. Hospitals often maintain several agents because resistance mechanisms vary by institution and patient population. Formulary placement depends on local antibiograms, infectious-disease specialist preference, acquisition cost, renal dosing, susceptibility results, and stewardship policy.
What is the financial trajectory for meropenem/vaborbactam?
Vabomere is a specialized hospital product rather than a mass-market antibiotic. Its revenue trajectory is driven by resistant infections, hospital adoption, and price realization.
| Financial driver |
Effect on Vabomere |
| Rising CRE prevalence |
Increases clinical need |
| KPC prevalence |
Directly supports use |
| Antimicrobial stewardship |
Restricts empiric use but supports targeted use |
| Hospital budget pressure |
Limits price expansion |
| Competing beta-lactamase inhibitors |
Reduces share concentration |
| Generic entry |
Creates material post-entry price erosion |
| IV administration |
Limits outpatient volume |
| Clinical guideline support |
Supports use in KPC infections |
| Private ownership structure |
Limits public product-level financial disclosure |
The product’s financial trajectory likely follows a two-stage pattern.
Near-term trajectory before generic entry
Before core-patent expiry, revenue can remain stable or grow modestly if CRE incidence rises and hospitals adopt rapid molecular diagnostics. Growth is constrained by stewardship programs, which reserve Vabomere for documented or strongly suspected resistant infections.
Pricing power is also limited. Hospitals negotiate through group purchasing organizations and often compare Vabomere against Avycaz, Recarbrio, Fetroja, and older generic therapies.
Post-generic trajectory
After generic entry, the likely outcome is a sharp decline in branded volume and net price. Hospital demand may shift rapidly if the generic is therapeutically substitutable and receives favorable contracting terms.
The decline could be less severe than for a high-volume outpatient product if:
- The generic supply base is limited.
- Sterile manufacturing capacity is constrained.
- Hospitals retain the branded product because of supply reliability.
- The originator negotiates an authorized-generic or co-marketing arrangement.
- Clinical protocols distinguish the branded product from lower-cost alternatives.
Public filings from the current private ownership structure do not provide a consistent standalone revenue series for Vabomere. The commercial asset should therefore be valued through prescription and hospital-utilization data, contract pricing, patent timing, and resistant-pathogen epidemiology rather than reported segment revenue.
What licensing deals and ownership changes affect Vabomere?
Vabomere originated with Rempex Pharmaceuticals and progressed through The Medicines Company’s antibiotic portfolio. Melinta acquired The Medicines Company’s infectious-disease assets and commercialized Vabomere. Melinta later underwent financial restructuring and changes in ownership, which affected portfolio reporting and reduced transparency around product-level sales.[5]
The ownership history matters for licensing and business-development analysis because Vabomere has been managed within antibiotic portfolios that also included Orbactiv, Minocin IV, Vabomere, and other hospital products. Portfolio bundling can improve sales coverage but can also shift investment toward products with faster commercial returns.
No major publicly disclosed licensing transaction has converted Vabomere into a broad global platform product. The asset remains primarily a hospital anti-infective with value concentrated in the United States and selected international markets.
What generic launch risks exist by geography?
Patent exposure is jurisdiction-specific. The United States has the clearest Orange Book and Paragraph IV framework. European and other markets depend on national patent validation, supplementary protection certificates, regulatory data protection, and local procurement rules.
| Geography |
Main entry barrier |
| United States |
Orange Book patent, Paragraph IV litigation, 30-month stay |
| European Union |
Validated patents, SPC status, national litigation |
| Japan |
Local patent term and regulatory exclusivity |
| Emerging markets |
Patent enforceability, procurement, local manufacturing, price controls |
| Hospital tenders |
Contract cycles and supply qualification |
International revenue is likely more exposed to tender competition and price erosion than U.S. revenue. In low- and middle-income markets, the key barrier may be product availability and hospital purchasing capacity rather than patent duration.
Key Takeaways
- Meropenem/vaborbactam is a targeted hospital antibiotic with its strongest value in KPC-producing CRE infections.
- FDA approval occurred on August 29, 2017; QIDP exclusivity expired in approximately August 2022.
- U.S. patent protection associated with Vabomere extends to approximately 2032, subject to final patent-term calculations.
- The product is exposed to Paragraph IV challenges and eventual generic competition, but no biosimilar risk exists.
- Avycaz, Recarbrio, Fetroja, and Zerbaxa create substantial therapeutic and formulary competition.
- Revenue growth depends more on resistant-pathogen prevalence and hospital adoption than on broad prescription expansion.
- Standalone product revenue is not consistently disclosed under the current private ownership structure.
- The largest long-term financial event is likely generic entry, followed by hospital contracting-driven price erosion.
FAQs
Is meropenem/vaborbactam a carbapenem antibiotic?
It is a combination of the carbapenem meropenem and the beta-lactamase inhibitor vaborbactam. Vaborbactam protects meropenem from certain beta-lactamases, especially KPC enzymes.
Does Vabomere treat metallo-beta-lactamase infections?
Generally, no. Vaborbactam does not inhibit metallo-beta-lactamases such as NDM, VIM, or IMP. Treatment must be guided by susceptibility testing and the resistance mechanism.
Can a generic version of Vabomere be approved before 2032?
Potentially. An ANDA applicant could challenge the listed patent through a Paragraph IV certification or obtain a license. Patent litigation, settlement terms, and FDA approval timing would determine the launch date.
Is Vabomere protected by a supplementary protection certificate in Europe?
European protection depends on country-specific patent validation and any granted supplementary protection certificate. The U.S. Orange Book does not determine European entry timing.
Why is Vabomere commercially important despite limited volume?
Its value comes from treating high-cost, difficult-to-manage resistant infections where ineffective therapy can increase mortality, length of stay, and hospital costs. That clinical value supports targeted use even though total patient volume is limited.
References
- U.S. Food and Drug Administration. (2017). FDA approves new antibacterial drug Vabomere. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Vabomere. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.
- Infectious Diseases Society of America. (2024). IDSA 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. https://www.idsociety.org
- Melinta Therapeutics. (2020). Corporate and restructuring disclosures. https://www.melinta.com
